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Background: Tissue invasion and metastasis are acquired abilities of cancer and related to the death in oral
squamous cell carcinoma (OSCC). Emerging observations indicate that the epithelial-to-mesenchymal transition
(EMT) is associated with tumor progression and the generation of cells with cancer stem cells (CSCs) properties.
Membrane Type 1 Matrix Metalloproteinase (MT1-MMP) is a cell surface proteinase, which is involved in degrading
extracellular matrix components that can promote tumor invasion and cell migration.
Methods: In the current study, we utilized SCC9 cells stably transfected with an empty vector (SCC9-N) or a vector
encoding human MT1-MMP (SCC9-M) to study the role of MT1-MMP in EMT development.
Results: Upon up-regulation of MT1-MMP, SCC9-M cells underwent EMT, in which they presented a fibroblast-like
phenotype and had a decreased expression of epithelial markers (E-cadherin, cytokeratin18 and β-catenin) and an
increased expression of mesenchymal markers (vimentin and fibronectin). We further demonstrated that MT1-MMP
-induced morphologic changes increased the level of Twist and ZEB, and were dependent on repressing the
transcription of E-cadherin. These activities resulted in low adhesive, high invasive abilities of the SCC9-M cells.
Furthermore, MT1-MMP-induced transformed cells exhibited cancer stem cell (CSC)-like characteristics, such as low
proliferation, self-renewal ability, resistance to chemotherapeutic drugs and apoptosis, and expression of CSCs
surface markers.
Conclusions: In conclusion, our study indicates that overexpression of MT1-MMP induces EMT and results in the
acquisition of CSC-like properties in SCC9 cells. Our growing understanding of the mechanism regulating EMT may
provide new targets against invasion and metastasis in OSCC.
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Oral squamous cell carcinoma (OSCC) is a major oral cav-
ity health problem. Although many therapeutic strategies
have been carried out [1], the 5-year survival rate for these
patients has remained at 50–60% for the last three decades
[2]. Tissue invasion and metastasis are exceedingly com-
plex processes and are one of the hallmarks of cancer [3];
thus, it is important to clarify the biological mechanism of* Correspondence: liulaikui@126.com
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reproduction in any medium, provided the ortissue invasion and metastasis for grading the course of
cancer and developing more effective therapies [3,4].
The epithelial-to-mesenchymal transition (EMT) is the
cellular and molecular process through which cell-to-cell
interactions and apico-basal polarity are lost and a mes-
enchymal phenotype is acquired, which are required for
cell motility and basement membrane invasion during
metastasis [5,6]. The EMT plays a critical role in em-
bryogenesis and is associated with tissue remolding,
wound healing, fibrosis, cancer progression and metasta-
sis [5,7-9]. In the metastatic cascade of epithelial tumors,
the EMT has been established as an important step [10].
Furthermore, researchers have shown that the EMT is
associated with the dedifferentiation program that leadsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cancer cells an efficient migration ability and a selective
advantage to reach distant locations [9,10]. Transcriptional
repression of the E-cadherin gene can lead to the loss of
the epithelial phenotype and the functional loss of E-
cadherin is one of the hallmarks of EMT [5]. In particular,
transcriptional repressor has recently emerged as a funda-
mental mechanism for the silencing of CDH1 (the gene
that encodes E-cadherin), such as the Snail (Snail1 and
Slug), ZEB (ZEB1 and ZEB2) and basic helix-loop-helix
(bHLH: Twist) families [6,11].
Matrix metalloproteinases (MMPs) are zinc-dependent
endopeptidases. MMPs are involved in degrading extra-
cellular matrix (ECM) in normal physiological processes,
such as embryonic development, reproduction and tissue
remodeling, as well as in disease processes, such as arth-
ritis and metastasis [12,13]. There are over 23 MMPs
identified in humans, which are subdivided into soluble
MMPs and membrane-type MMPs (MT-MMPs) [14,15].
While MT1-MMP has a common MMP domain struc-
ture with a signal peptide, a pro-peptide, catalytic and
hemopexin-like domains, it also has unique insertions.
One of the insertions is at the C-terminus and contains a
hydrophobic amino-acid sequence that acts as a trans-
membrane domain [16,17]. As a member of the MMPs,
MT1-MMP is closely associated with cancer invasiveness
and the promotion of cell migration [16,18-20]. Recent
researches have emerged to indicate that cell surface
MT1-MMP has been recognized as an inducer of EMT in
cancer cells [21,22]. The researches on MT1-MMP further
demonstrated that MT1-MMP via cleaving E-cadherin in-
duced an EMT in transfected breast cancer [21], which
was shown to be dependent on up-regulation of Wnt5a in
prostate cancer cells [22]. However, the molecular tran-
scriptional mechanism related to MT1-MMP as an in-
ducer of EMT remains poorly understood, and the
association of MT1-MMP and EMT has not been
reported in oral cancer cells. Thus, we examined whether
MT1-MMP-induced EMT through mediation of tran-
scriptional repression of E-cadherin in OSCC.
Recently, studies of neoplastic tissues have provided evi-
dence of self-renewing, stem-like cells within tumors,
which have been called cancer stem cells (CSCs) [23]. In-
creasing evidence suggests that EMT bestows carcinoma
cells at the tumor front with cancer stem cell (CSC)-like
properties and plays an important role in initiating CSCs
[24,25]. Furthermore, CSCs have been identified in head
and neck SCC [4,25]. However, an association specifying
the EMT and CSCs induced by MT1-MMP in SCC9 cells
has not been investigated.
Based on the above studies, we demonstrate the mo-
lecular mechanisms in OSCC that are involved in the
overexpression of MT1-MMP by the cancer cells that
induces an EMT and leads to the acquisition of CSC-likeproperties by the cancer cells. These studies may provide
new avenues of research with potential clinical implications.
Methods
Cell cultrue, plasmid construction and transfection
Human oral squamous cell carcinoma SCC9 cells were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). Cells were maintained in a
mixture of Dulbecco’s Modified Eagle’s medium and
Ham’s F12 medium (1:1) (Invitrogen, Burlington, Ontario,
Canada) supplemented with 10% fetal bovine serum (FBS,
Invitrogen), 400 ng/ml hydrocortisone (Sigma-Aldrich, St
Louis, MO, USA) and penicillin (100 U/ml)/streptomycin
(100 μg/ml) (Invitrogen). A full-length cDNA for human
MT1-MMP (NM_004995.2) was amplified using RT-PCR
and then ligated into the PCR2.1-TOPO vector. The
constructed PCR gene product was cloned into the
pEGFP-N1 vector. The final gene synthesis was verified
via sequencing and amplified using DH5α competent cells.
The Endo-free Plasmid Mini Kit II (OMEGA) was used for
all plasmid preparations. For transfection experiments, cells
were maintained in six-well plates (Corning, Lowell, MA,
USA) and cultured to 80% confluence, after which the
medium was changed to serum-free medium for overnight
incubation. The cells were transfected with Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instruc-
tions. G418 (400 μg/ml; Invitrogen) was added to the
media 48 h after transfection. The cells were allowed to
grow in the presence of G418 for two weeks, and clones
were picked for growth on plates to confluence. Thus,
stably expressing empty vector--SCC9-pEGFP-N cells
(SCC9-N) and a vector encoding human MT1-MMP–
SCC9-pEGFP-M cells (SCC9-M) were obtained for our
study.
For the experiment of addition of inhibitors, 2×105/ml
SCC9-M cells were added to six-well plates (Corning).
The cells were then treated with 5 nM tissue inhibitor of
metalloproteinase (TIMP)-1 (Calbiochem, Darmstadt,
Germany), 5 nM of TIMP2 (Calbiochem) and incubated
for three days at 37°C.
Real-time RT-PCR
Total RNA was extracted from cells using the TRIzol re-
agent (Invitrogen). For cDNA synthesis, mRNA was
reverse-transcribed into cDNA using the 5×PrimeScript
RT Master Mix (TaKaRa) at 37°C for 15 min and 85°C
for 5 s according to the manufacturer’s protocol. Gene
expression was quantified by real-time quantitative PCR
using 2×SYBR Premix Ex Taq (TaKaRa) with a 7300 ABI
Real-Time PCR System (Applied Biosystems, Foster City,
CA, USA) under the conditions of 95°C for 30 s, 95°C
for 5 s, and 60°C for 31 s for 40 cycles. The relative gene
expression was calculated using the 2(−ΔΔCT) method.
Briefly, the resultant mRNA was normalized to its own
Yang et al. BMC Cancer 2013, 13:171 Page 3 of 12
http://www.biomedcentral.com/1471-2407/13/171GAPDH [26]. The following primers were utilized for the
real-time RT-PCR. GAPDH (50-GAAGGTGAAGGTCGGA









CAACGGCAAAGTTC-30), fibronectin (50 –TGCCTTGC
ACGATGATATGGA-30, 50-CTTGTGGGTGTGACCTG
AGTGAA-30), snail (50-GACCACTATGCCGCGCTCTT-





30, 50-TTTGGGCGGTGTAGAATCAGAG-30), ZEB2 (50-
AAATGCACAGAGTGTGGCAAGG-30, 50-CTGCTGAT
GTGCGAACTGTAGGA-30) and CDH1 (50-AGATGGTG
TGATTACAGTCAAAAGG-30, 50-CAGGCGTAGACCA
AGAAAT-30).
Western blotting and shedding of the E-cadherin
ectodomain
Cells were lysed using a RIPA lysis buffer (Beyotime).
Total protein (30 μg) from each sample was subjected to
the SDS-PAGE and then transferred to PVDF membranes
(Millipore, Billerica, MA, USA), which were blocked for 2
h at room temperature with 5% nonfat milk in PBST. The
following antibodies were used to detect bands on the pro-
tein blots: anti-β-actin (1:1000, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti-MT1-MMP (1:500, Abcam,
Cambridge, MA, USA), anti-E-cadherin (1:1000, Cell Sig-
naling Technology, Danvers, MA, USA), anti-β-catenin
(1:500, Santa Cruz Biotechnology), anti-cytokeratin18
(1:500, Bioworld Technology, MN, USA), anti-vimentin
(1:500, Santa Cruz Biotechnology), anti-fibronectin (1:500,
Santa Cruz Biotechnology), anti-Snail (1:500, Abcam),
anti-Slug (1;1000, Cell Signaling Technology), anti-Twist
(1:500, Abcam), anti-ZEB1 (1:300, Abcam) and anti-ZEB2
(1:500, Novus Biologicals, Littleton, USA). Immunoreac-
tive material was visualized using the Immun-Star
WesternC Kit (Bio-Rad, Hercules, CA, USA) products and
bands were detected via exposure to film (Kodak, Japan).
For detecting the expression of extracellular E-cadherin,
the cells were cultured with serum-free medium for 24 h.
Next, the conditioned medium was collected via centrifu-
gation and concentrated 10-fold with a VirTis freeze dryer
(SP Scientific, NY, USA). An immunoblot was performed
as described above using an anti-E-cadherin ectodomain
antibody (1:500, Santa Cruz Biotechnology). All westernbolt analyses were performed at least three independent
experiments.
Immunofluorescence
Cells were cultured on glass coverslips, fixed in 4% para-
formaldehyde (PFA) for 20 min at room temperature,
permeabilized with 1% Triton X-100 for 15 min and
blocked with goat serum albumin for 30 min 37°C,
followed by an overnight incubation at 4°C with antibodies
specific for E-cadherin (1:100, Cell Signaling Technology)
and vimentin (1:100, Santa Cruz Biotechnology), or
cytokeratin 18 (1:100, Bioworld technology) and fibronec-
tin (1:100, Santa Cruz Biotechnology). The appropriate
secondary antibodies (diluted 1:50) were then used, and
then nuclei were stained by 4, 6-diamidino-2-phenylindole
(DAPI; 1:1000, Invitrogen) for 2 min. Immunofluorescence
was visualized using a Zeiss LSM-710 laser-scanning con-
focal microscopy.
Adhesion, invasion and wound healing assays
The cells were plated in six-well plates (Corning) at a
density of 4×105 per well and then trypsinized after 1
and 2 h, respectively. The attached cells were counted
under an inverted microscope (Olympus), and the adher-
ent rate of the three different cell populations was calcu-
lated. The cell invasion was assessed using Transwell
filters with 6.5-mm diameters and 8-μM pore sizes
(Costar, Lowell, MA, USA). The filters were precoated
for 30 min at 37°C with 50 μL per square centimeter of
growth surface with Matrigel Basement Membrane
Matrix (BD Biosciences, MA, USA) diluted with serum-
free medium (1:3) according to the manufacturer’s pro-
cedures. The cells (3×105) were resuspended with 100 μl
serum-free medium inoculated in the upper chamber
while 500 μl medium containing 10% FBS was placed in
the lower chamber. The plates were placed at 37°C in
5% CO2 for 24 h. The chambers were fixed with 4% PFA
and stained with 0.1% crystal violet (Beyotime) for 30
min. The non-migratory cells were removed, and the mi-
gratory cells were counted as those presenting on the
lower surface of the upper chamber. Images of at least
ten random fields per chamber were captured (×100
magnification). For the wound healing assay, the cells
were allowed to grow to 90% confluence and then
wounded by scratching with a pipette tip in the central
area. Floating cells and debris were removed, and the
medium was changed to serum-free. The cells were in-
cubated for 48 h to allow cells to grow and close the
wound. Photographs were taken at the same position of
the wound at the indicated time points.
Flow cytometry
For flow cytometric cell-cycle analysis, the cells were
synchronized with serum-free medium for 24 h, released
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from the culture plate with trypsin, washed with PBS, and
then resuspended in 75% alcohol. The prepared cells were
stained with 100 mg/ml of propidium iodide (BD
Pharmingen, San Jose, CA, USA) prior to analysis using
flow cytometry with a BD FACS Calibur (BD Biosciences)
and CellQuest Pro software (BD Biosciences). For surface
marker analysis, the cells were collected and then labeled
with human-fluorochrome-conjugated anti-CD24-PE (10
μl per test, Beckman Coulter, Los Angeles, CA, USA),
anti-CD44-APC (20 μl per test, BD Pharmingen), anti-
CD133-PE (10 μl per test, Miltenyi Biotech, Auburn, CA,
USA). The corresponding mouse immunoglobulins conju-
gated to PE or APC (BD Pharmingen) were used as
isotype controls in each experiment. For apoptosis ana-
lysis, the cells were dealed with mitomycin at concentra-
tion gradients of 16 and 128 mg/ml for 24 h. Then the
prepared cells were collected and stained with PE Annexin
V Apoptosis Detection Kit I (BD Pharmingen) for 15 min
according to the manufacturer’s protocol. The rate of
apoptosis cells was relative to each untreated group.
Colony-forming assays
The cells were plated in 100-mm dishes (Corning) at a
density of 1000 cells per dish and cultured at 37°C for two
weeks. The dishes were fixed in 4% PFA, stained with crys-
tal violet, and photographed. The colonies were visualized
under an inverted microscope (Olympus). Aggregations of
more than 50 cells were defined as a colony.
MTT assay
The survival rate of cells was analyzed using an MTT
(Sigma) assay, which is a colorimetric assay for measuring
the activity of enzymes that reduce MTT to formazan dyes,
producing a purple color. The MTT assay is the preferred
method used to assess the viability and proliferation of cells
[27]. The SCC9-N and SCC9-M cells were plated in 96-
well plates (Corning) at an initial density of 2×103 cells per
well, and then synchronized with serum-free medium for
24 h. For consecutive culturing at 0, 1, 3, 5, 7, 9 d, the cells
were treated with 5 mg/ml MTT and incubated at 37°C for
4 h, and then treated by dimethylsulfoxide (Sigma). The
absorbance of samples in triplicate wells was measured
with an automatic enzyme-linked immunosorbent assay
reader (ELx800, BioTek Instruments, Inc., USA) at a wave-
length of 490 nm. Population doubling time (PDT) was
calculated according to Patterson formulation. For drug re-
sistant experiment, the SCC9-N and SCC9-M cells were
plated in 96-well plates (Corning) at the same density of
5×104 cells. After serum-starvation, mitomycin at concen-
tration gradients of 16 and 128 mg/ml was added separ-
ately to the culture medium and maintained for 24 h. The
absorbance of samples in triplicate wells was measured as
introduced above. The survival rate of the cells relative toeach untreated group was calculated. The data were ana-
lyzed using three independent experiments.
Statistical analysis
The data were representative of three or more independent
experiments as the mean ± s.d. Statistical significance was
assessed using one-way analysis of variance and Student’s
unpaired t test. P-value <0.05 was considered significant.
Results
Human oral squamous cell carcinoma SCC9 cells are
less aggressive, which may correlate with the low MT1-
MMP expression level observed in these cells. Thus, we
utilized the up-regulation of MT1-MMP in SCC9 cells, via
the transfection of either an empty vector (SCC9-N) or a
vector encoding human MT1-MMP (SCC9-M), to study
the role of MT1-MMP in cancer invasion and metastasis.
After screening via G418 selection, we performed a series
of experiments using SCC9 cell lines stably expressing
empty vector or MT1-MMP.
MT1-MMP induces SCC9 cells to undergo an EMT and
alters cell phenotype
Overexpression of MT1-MMP in SCC9 cells results in
morphologic changes of cells that are undergoing an
obvious EMT. The observed morphological changes ob-
served include cells switching from a cuboid epithelial
shape to a fibroblastic appearance, which was not ob-
served in cells expressing a control empty vector. The
same changes can be viewed under a fluorescence micro-
scope (Figure 1A and B). The quantitative determination
of the mRNA expression in SCC9-M cells using real-time
RT-PCR revealed that a loss of the epithelial markers E-
cadherin, cytokeratin 18 and β–catenin occurred when
compared with that of GAPDH. Simultaneously, an
up-regulation of the mensenchymal markers vimentin
and fibronectin was observed (Figure 1C). To verify
these findings on the protein level, a Western blot ana-
lysis was utilized to determine the expression of the
epithelial and mesenchymal markers. Notably, the
Western blot analysis confirmed the changes in gene
expression, as the increased expression of MT1-MMP
in SCC9 cells resulted in a decrease of E-cadherin,
cytokeratin 18, and β–catenin, and a concurrent in-
crease of vimentin and fibronectin (Figure 1D). To
confirm the effect of MT1-MMP on the EMT of the
cells, we used laser scanning confocal fluorescence mi-
croscopy to identify the expression of these epithelial and
mesenchymal markers. As shown with the immunofluor-
escence analysis, the SCC9-M cells presented a fibroblast-
like appearance, with decreased E-cadherin (red) and
cytokeratin 18 (red) and increased vimentin (orange) and
fibronectin (orange) protein expression. By contrast, the
SCC9-N cells retained an epithelial-like morphology with
Figure 1 MT1-MMP induces SCC9 cells to undergo an EMT and morphologic changes. (A) Stable expression of an empty vector or MT1-
MMP in SCC9 cells was established. Pictures were captured under fluorescence microscope. Bar, 100 μm. (B) Stable SCC9 cells expressing empty
control vector (SCC9-N) possessed a typical epithelial phenotype, similar to parental SCC9 cells. Stable SCC9 cells expressing MT1-MMP (SCC9-M)
possessed an elongated, fibroblastic appearance. Photographs were taken under inverted microscope (Olympus). Bar, 100 μm. (C) Quantitative
determination of mRNA expression of epithelial markers (E-cadherin, cytokeratin 18 and β–catenin) and mesenchymal markers (vimentin and
fibronectin) in SCC9, SCC9-N, SCC9-M cells using real-time RT-PCR. GAPDH was used as a control. Each bar represents the mean ± s.d. *P<0.05,
**P<0.01. (D) The EMT-related protein levels were characterized by Western blot analysis. β-actin was employed as a loading control.
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weak vimentin and fibronectin expression, similar to par-
ental SCC9 cells (Figure 2A and B). These results demon-
strated that increased MT1-MMP expression was capable
of inducing an EMT in SCC9 cells.
MT1-MMP induces EMT is associated with an increase of
Twist and ZEB and through repressing the transcription
of E-cadherin
The loss of functional E-cadherin is a hallmark of EMT [5]
and is considered a prerequisite. To investigate the mech-
anism by which MT1-MMP induces SCC9 cells to undergo
EMT, we detected the gene expression of CDH1 that en-
codes E-cadherin in SCC9, SCC9-N and SCC9-M cells,
and also detected the expression of key transcriptional re-
pressors of CDH1 as inducers of EMT. The result of real-
time RT-PCR showed that the level of CDH1 wasdecreased to 0.0018-fold in SCC9-M cells relative to the
SCC9 and SCC9-N cells (Figure 3A). Elevated levels of the
mRNA for three key EMT-inducing transcription factors,
Twist (9.55-fold), ZEB family-ZEB1 (602.03-fold) and ZEB2
(49.79-fold), were observed in SCC9-M cells relative to the
SCC9 and SCC9-N cells. However, there was no significant
difference in mRNA expression in Snail family members
(Snail and Slug), as determined by real-time RT-PCR in the
three cell lines (Figure 3B). Next, we proceeded to analyze
the expression of these transcriptional repressors at the
protein level. The Western blot trends corresponded to the
real-time RT-PCR results (Figure 3C). A reduction of Twist
(28.61%), ZEB1 (47.18%) and ZEB2 (45.92%) could be ob-
served with SCC9-M cells in the presence of recombinant
TIMP2 (5 nM, an inhibitor of MT1-MMP) but not TIMP1
(5 nM, an MMP inhibitor that does not specific affect
MT1-MMP). The expression of CDH1 in SCC9-M cells
Figure 2 Immunofluorescence analysis of SCC9 cells, stable SCC9 cells expressing an empty vector (SCC9-N) and MT1-MMP (SCC9-M).
(A) Double immunofluorescence staining of E-cadherin (E-cad: red) and vimentin (Vim: orange). (B) Double immunofluorescence staining of
cytokeratin 18 (KRT 18: red) and fibronectin (FN: orange). The nuclei in both image sets were stained with DAPI (blue). Images were taken at ×400
magnification. Bar, 100 μm.
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TIMP1 (Figure 3D and E). These results suggested that an
MT1-MMP directed the process that regulating the ex-
pression of Twsit, ZEB and CDH1. Furthermore, the
examination of the shedding of E-cadherin extracellular
domains in conditioned medium was nearly undetected in
SCC9-M cells (Figure 3F). These data indicated that the
MT1-MMP-induced EMT was associated with an in-
creased level of Twist and ZEB family and was dependent
on repressing the transcription of E-cadherin.
Overexpression of MT1-MMP in SCC9 cells results in a
change in the biological properties of the cells
In previous studies, the mesenchymal cells were highly in-
vasive and metastatic, with a loss of cell-to-cell adhesion
[28]. To identify whether MT1-MMP induces this ability
of SCC9 cells to gain the mesenchymal-like appearances
with these characteristics, we performed a series of experi-
ments. First an adhesion test demonstrated that the
SCC9-M cells had a lower adhesive ability than the SCC9and SCC9-N cells (Figure 4A). The adherent rate of the
cells at one hour was 18.95%, 15.63% and 12.71% for the
SCC9, SCC9-N and SCC9-M cells, respectively. At two
hours, the percentage of attached cells for the three cell
lines was 48.46%, 49.79%, and 31.04%, respectively. Next, a
Transwell assay was performed to evaluate the invasive
ability of SCC9-M cells. After 24 h, the ability of the cells
to penetrate Matrigel basement membrane matrix was
quantified and captured with ×100 magnification in ten
random fields. The photographs demonstrated that the
SCC9-M cells were more invasive than SCC9 and SCC9-
N cells. The quantitative analysis revealed an increase of
2.84-fold or 3.38-fold over that observed for SCC9 or
SCC9-N cells (Figure 4B and C). These results demon-
strated that increased expression of MT1-MMP promoted
the invasive ability of SCC9 cells. The result of scratch test
showed that the SCC9 and SCC9-N cells migrated to con-
fluence after 48 h; however, the SCC9-M cells exhibited
no ability to close the wound (Figure 5). Previous study
suggested that wound-healing assays had been carried out
Figure 3 MT1-MMP induces SCC9 cells to undergo EMT is associated with an increased level of Twist and ZEB and through repressing
the transcription of E-cadherin. (A) Real-time RT-PCR was performed to detect the expression of CDH1 that encoding E-cadherin in SCC9 cells,
stable SCC9 cells expressing an empty vector (SCC9-N) and MT1-MMP (SCC9-M). GAPDH was used as a control. Each bar represents the mean ± s.
d. ***P<0.001. (B) Real-time RT-PCR was performed to detect the key transcription factors that repressed CDH1 as inducers of EMT, including Snail,
Slug, Twist, ZEB1 and ZEB2. GAPDH was used as a control. Each bar represents the mean ± s.d. **P<0.01. (C) Western blot was performed to
analyze the expression of transcriptional repression factors on the protein level. β-actin was employed as a loading control. (D and E) Quantitative
determination of mRNA expression of transcription factors on the SCC9-M cells treated with TIMP1 and TIMP2. Each bar represents the mean ± s.
d. *P<0.05. The western blot analysis was performed to assess the expression of transcription factors on the SCC9-M cells treated with TIMP1 and
TIMP2 on the protein level. β-actin was employed as a loading control. (F) The examination of the shedding of E-cadherin extracellular domain in
conditioned medium and cell surface of SCC9, SCC9-N and SCC9-M.
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tion rates and migratory behavior associated with different
cells and culture conditions [29]. This result illuminated
that the more invasive SCC9-M cells presented to a low
growth ability, which was correlated with the phenomenon
observed during cell culture. Previous study showed that
there existed a subpopulation of tumor cells with stem
cell-like characteristics such as very slow replication and
resistance to chemotherapy [30]. Thus, we speculated that
overexpression of MT1-MMP in SCC9 cells resulted in the
cells undergoing an EMTand presented lower proliferation
ability that may confer CSC-like properties.
Overexpression of MT1-MMP in oral cancer cells results in
the expression of CSC-like characteristics
Head and neck squamous cell carcinoma (HNSCC) con-
tain a subpopulation of cancer cells that are capable of
self-renewal, are able to proliferate and form new tumors,
and possess the features of CSCs [4]. Previous studies onCSCs revealed that CSCs retain the properties of relative
quiescence as well as resistance to therapeutic drugs and
apoptosis [31,32]. To verify that SCC9-M cells had low
proliferation abilities as shown in the scratch test, a cell-
cycle analysis was performed. The SCC9-M cells had a
higher percentage of cells in the G0/G1 phase (29.51%)
than that observed for the SCC9-N cells (19.05%). In con-
trast, the total percentage of cells in S-phase was 18.36%
for the SCC9-M cells, which is lower than the 22.78% ob-
served for the SCC9-N cells, confirming that the SCC9-M
displayed decreased proliferation ability (Figure 6A). An
MTT assay was performed to further determine that the
SCC9-M cells displayed a lower cell proliferation. As shown
in cell growth curve, the PDT in SCC9-M cells (46.38 ±
1.14 h) was significantly longer than in SCC9-N cells
(29.36 ± 1.35 h) (Figure 6B). Next we examined the ex-
pression levels of several CSCs surface markers by flow cy-
tometry. The SCC9-M cells presented as CD44+ (93.45%)
CD24-low (49.21%) CD133- (0.89%), while SCC9-N cells
Figure 4 The examination of the biological properties of SCC9 cells, stable SCC9 cells expressing an empty vector (SCC9-N)
and MT1-MMP (SCC9-M). Overexpression of MT1-MMP in SCC9 cells resulted in a low adhesive, high invasive ability. (A) The quantification of
cell adhesion rate at two time points. Each bar represents the mean ± s.d. **P<0.01. (B) Quantitative analysis of cell invasion in ten different
random fields. The data were calculated as the mean ± s.d. **P<0.01. (C) Pictures presenting the cells penetrating the Matrigel basement
membrane matrix after 24 h. Bar, 100 μm.
Figure 5 The wound healing assay indicated that SCC9 cells transfected with MT1-MMP (SCC9-M) did not have the ability to close the
wound after 48 h. Photographs were taken at the same position of the wound at the indicated time points (×40 magnification). Bar, 100 μm.
K, SCC9 cells. N, stable SCC9 cells expressing empty vector. M, stable SCC9 cells expressing vector encoding MT1-MMP.
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Figure 6 Stable SCC9 cells expressing MT1-MMP (SCC9-M) presented cancer stem cell (CSC)-like properties of expressing CSC markers,
self-renewal and resistance to drugs. (A) Cell-cycle analysis of stable SCC9 cells expressing empty vector (SCC9-N) and MT1-MMP (SCC9-M).
(B) Growth curves of SCC9-N and SCC9-M cells. The bar represents the mean ± s.d. (C and D) The flow cytometry analysis of CSC markers,
including the CD24, CD44, and CD133 expression, in the SCC9-N and SCC9-M cells. The corresponding mouse immunoglobulins conjugated to
PE or APC were used as isotype controls in each experiment. (E) Images of colonies stained with crystal violet for the SCC9-N and SCC9-M cells.
(F) The pictures of cells forming single colony under microscopy. The photographs were taken at ×40 magnification. Bar, 100 μm.
(G) Quantification of colonies formed by the SCC9-N and SCC9-M cells. The bar represents the mean ± s.d. **P<0.01. (H) The survival rate of
SCC9-N and SCC9-M cells by the treatment with mitomycin after 24 h. Each bar represents the mean ± s.d. *P<0.05, **P<0.01.
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(0.29%) (Figure 6C and D). A colony-forming assay was
performed and confirmed that the SCC9-M cells had the
ability to self-renew but formed fewer colonies than SCC9-
N cells (Figure 6E-G). This result provided additional evi-
dence that the SCC9-M cells had a lower proliferation ability
than SCC9-N cells. To further investigate whether SCC9-M
cells developed resistance to therapeutic drugs, mitomycin
was administered to the cells for 24 h. As shown in
Figure 6H, the SCC9-M cells had a higher survival rate
than SCC9-N cells by treating with different drug concen-
trations (16 and 128 mg/ml). This result revealed that the
up-regulation of MT1-MMP in SCC9 cells contributed to
drug resistance of the cells. To determine the ability ofresistance to apoptosis in SCC9-M cells, a flow cytometric
apoptosis analysis was performed. For SCC9-M cells, the rate
of apoptosis cells was lower than SCC9-N cells treated with
mitomycin at the drug concentrations of both 16 and 128
mg/ml for 24 h (Figure 7A and B). Our results suggested
that there existed significantly higher population of SCC9-
M cells resistance to apoptosis, as shown in the statistical
analysis in Figure 7C.
Discussion
Most patients with OSCC die because of metastasis or re-
currence of the tumor [2]. However, key events mediating
invasion and metastasis of this carcinoma are still un-
defined, although the linkage between an EMT and cancer
Figure 7 Stable SCC9 cells expressing MT1-MMP (SCC9-M) possessed the ability of more resistant to apoptosis. (A and B) The flow
cytometric apoptosis analysis for stable SCC9 cells expressing an empty vector (SCC9-N) and SCC9-M cells under two concentrations of
mitomycin. (C) The statistic analysis of the rate of cell apoptosis for the SCC9-N and SCC9-M cells. Each bar represents the mean ± s.d. **P<0.01.
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[5,8-10]. Studies have suggested that EMT endows cells
with stem cell-like traits [26,32,33] and allows to become
more invasive and migratory. Thus, our research was fo-
cused on the association of MT1-MMP, EMTand invasion
and metastasis of oral carcinoma SCC9 cells; and, we
made four novel observations. First, overexpression of
MT1-MMP can induce oral cancer SCC9 cells to undergo
EMT. Second, MT1-MMP-induced phenotypic changes in
the SCC9 cells increased the level of Twist and ZEB and
were dependent on repressing the transcription of E-
cadherin. Third, this phenotype transformation resulted in
a change in the biological properties of the cells, with the
cells having decreased adhesion, high invasion but low
proliferation ability. Fourth, these mesenchymal-like cells
gained CSCs features.
MT1-MMP was recognized as a key mediator in both
ECM remolding and cell migration during tumor progres-
sion [17,19]. Previous studies on MT1-MMP were focused
on the relationship of its domain structures and cancer in-
vasion and metastasis. Our study related to the connection
of MT1-MMP and the EMT revealed that up-regulation
of MT1-MMP can induce oral carcinoma SCC9 cells to
undergo EMT via transcriptional repression of E-cadherin.
Upon the overexpression of MT1-MMP, SCC9-M cells
presented a fibroblast-like phenotype compared with the
cubic epithelial phenotype of SCC9-N cells. In addition,
analysis of the mRNA and protein levels verified that the
SCC9-M cells underwent an EMT, in which decreased ex-
pression of epithelial markers (E-cadherin, β-catenin,
cytokeratin 18) and increased expression of mesenchymal
markers (vimentin, fibronectin) were observed. Further-
more, overexpression of MT1-MMP in SCC9 cells resultedin a change in the biological properties of the cells. The
SCC9-M cells lost the need for cell-to-cell adhesion which
contributed to cells becoming motile. As shown in invasion
assay, the SCC9-M cells acquired a highly invasive ability.
This in turn may allow cancer cells to cross the basement
membrane and invade surrounding tissues. Importantly,
recent studies demonstrated that MT1-MMP was essential
for the invasive ability of cells, due to its broad-spectrum
activity of degrading ECM components [16,17,34,35]. Our
results verified that MT1-MMP promoted cancer cell inva-
sion in OSCC through inducing the EMT.
The EMT is an important step in the metastatic
process of epithelial tumors [10], for which recent studies
have provided a more in-depth understanding of the mo-
lecular mechanisms involved. Loss of E-cadherin is cen-
tral to EMT in cancer cells [5]. Thus, in the present
study, we focused our attention on the transcriptional re-
pression of E-cadherin to explain how MT1-MMP
caused EMT in SCC9 cells. We also done the research to
identify whether MT1-MMP overexpression resulted in
the shedding of E-cadherin to induce an EMT, similar to
that reported in prior studies [21,22]. However, an exam-
ination of extracellular E-cadherin in the conditioned
medium on SCC9-M cells was nearly undetectable, not
similarly as previously reported in prostate cancer. Our
results demonstrated that MT1-MMP played a role in
dynamic silencing of CDH1 so that transcriptional re-
pression of E-cadherin, leading to the loss of the epithe-
lial phenotype of SCC9 cells to undergo EMT. Indeed,
several transcription factors that strongly repress CDH1
(such as members of Snail, ZEB and bHLH families) have
recently emerged, which are now thought to be involved
in tumor progression [36]. The Snail family (Snail and
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http://www.biomedcentral.com/1471-2407/13/171Slug) was first identified as inducers of EMT [37,38], and
our previous work demonstrated that Snail had played an
important role in inducing an EMT in SCC9 cells [39].
However, in this study, no significant difference in the
expression of Snail and Slug were observed in the three
experimental cells. Furthermore, the level of mRNA and
protein expression observed on SCC9-M cells and SCC9-
M cells treated with TIMP1 and TIMP2 may demonstrate
that the MT1-MMP-induced EMT change was associated
with an increase of Twist and ZEB. Twist and ZEB genes
are key inducers of EMT and are closely associated with
tumor progression [40-42]. However, further investigation
is required, exploring the linkage between increased ex-
pression of both Twist and ZEB via MT1-MMP.
Furthermore, the more invasive SCC9-M cells did not
have the ability to close the wounds in the wound healing
assay. This result was consistent with our previous work
[39] and revealed that the SCC9-M cells exhibited a low
growth ability, which was further validated by cell-cycle
analysis and cell proliferation assay. The cell mitosis of
SCC9-M was blocked at the G0/G1 phase leading to a low
percentage of the cells residing in S-phase, suggesting a
decreased ability of cell growth. The cell growth curve
showed that the PDT in SCC9-M cells was significantly
longer than in SCC9-N cells, which further demonstrated
this point that the SCC9-M cells displayed lower prolifera-
tion ability. Although the SCC9-M cells had lower growth
ability, they possessed the ability of self-renewal, as dem-
onstrated in the colony-forming assay. The less visible and
smaller colonies formed by SCC9-M cells further eluci-
dated that the SCC9-M cells had lower proliferation abil-
ity. It has been proposed that most of the CSCs exist in
the quiescent G0 cell phase, which allows an escape from
anti-cancer drug targeting and resistance to apoptosis
[31]. In our study, the mesenchymal-like SCC9-M cells
shared the ability of chemotherapeutic resistance to mito-
mycin. The flow cytometric apoptosis analysis confirmed
that the SCC9-M cells are more resistant to apoptosis.
These results demonstrated that there existed more
SCC9-M cells in a relative quiescent state, and these non-
dividing SCC9-M cells shared the ability to resistance to
cell death which presented CSC-like properties. Recently,
many CSC signatures have been reported, such as CD24,
CD44, CD133 and so forth [4,25,43,44]. In the current
study, the SCC9-M cells possessed CD24low expression in
contrast to the CD24high expression of the SCC9-N cells,
while both cell populations were CD44high. The expression
of CD133 was either 0.89% or 0.29% in SCC9-M and
SCC9-N cells, respectively. This result was not the same
as that of prior reports; however, the CSC surface markers
are not consistent across various tumors. The marker may
or may not be useful for identifying stem cells from the
other organ or tumor type [45]. Our results demonstrated
that the cell surface marker CD44, while certified as aCSC marker in HNSCC, was not specific to oral SCC9
cells. Thus, it is not sufficient to define a stem cell solely
based on surface markers, and multiple assays are required
to isolate putative CSCs efficiently. Overall, our study
demonstrated that the SCC9-M cells possessed CSC-like
properties, including the ability to self-renew, resistance to
chemotherapeutic agents and apoptosis, and expression of
CSC markers.
Conclusions
In conclusion, our study demonstrated that MT1-MMP,
through repressing the transcription of E-cadherin, in-
duced less aggressive oral SCC9 cells to undergo an EMT,
which converted the SCC9-M cells into exhibiting a
mesenchymal-like phenotype, and to possess more inva-
sive ability. Furthermore, this transformation revealed a
connection with CSCs. Collectively, further detailed infor-
mation related to the molecular requirements for EMT
will contribute to a better understand of tumor progres-
sion and may suggest more efficient targets for future
therapeutic development.
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